{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-010337","form_type":"8-K","ticker":"ELAN","cik":"0001739104","company_name":"Elanco Animal Health Inc","filed_at":"2024-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.354388+00:00","generated_at":"2026-06-06T09:13:05.650320+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elanco sells aqua business to Merck Animal Health for $1.3B cash","bullets":["Transaction valued at approx. 7.4x estimated 2023 revenue of $175M and adjusted EBITDA of $92M.","After-tax proceeds of $1.05B-$1.1B to be used to pay down Term Loan B debt, reducing interest expense ~$65M annually.","Pro forma net leverage ratio would have been ~5.0x for 2023, down from slight below midpoint of 5.5x-5.8x guidance.","Expected close around mid-2024, subject to regulatory approvals and customary conditions.","Divestiture includes ~280 employees, manufacturing sites in Canada and Vietnam, and R&D projects."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-010337","json":"https://secwatch.observer/filing/0001104659-24-010337.json","markdown":"https://secwatch.observer/filing/0001104659-24-010337.md","text":"https://secwatch.observer/filing/0001104659-24-010337.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739104/000110465924010337/0001104659-24-010337-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739104/000110465924010337/tm245182d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:13:05.650320+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c1c36583a81b6d6bc66f4ba8da3a6d3a61ab78fb","claim":"Elanco Animal Health Inc entered into Asset Purchase Agreement with Intervet International B.V. valued at approximately $1.3 billion (effective 2024-02-05).","evidence_excerpt":"On February 5, 2024, Elanco Animal Health Incorporated, an Indiana corporation (“Elanco”), and Intervet International B.V., a Dutch private company with limited liability (“Buyer”), entered into an Asset Purchase Agreement (the “Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739104/000110465924010337/0001104659-24-010337-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Intervet International B.V."},{"label":"Value","value":"approximately $1.3 billion"},{"label":"Effective","value":"2024-02-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}